Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JACK A ROTH and RITSUKO KOMAKI.
JACK A ROTH
Connection Strength
2.168
RITSUKO KOMAKI
  1. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015 Jun; 16(6):630-7.
    View in: PubMed
    Score: 0.133
  2. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1120-8.
    View in: PubMed
    Score: 0.123
  3. A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors. Cancer. 2012 Jan 15; 118(2):444-51.
    View in: PubMed
    Score: 0.101
  4. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
    View in: PubMed
    Score: 0.096
  5. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):412-418.e1-2.
    View in: PubMed
    Score: 0.088
  6. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):967-71.
    View in: PubMed
    Score: 0.085
  7. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. J Thorac Cardiovasc Surg. 2005 Dec; 130(6):1601-10.
    View in: PubMed
    Score: 0.069
  8. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
    View in: PubMed
    Score: 0.066
  9. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23.
    View in: PubMed
    Score: 0.066
  10. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg. 2005 Feb; 79(2):391-7; discussionn 391-7.
    View in: PubMed
    Score: 0.065
  11. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
    View in: PubMed
    Score: 0.064
  12. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
    View in: PubMed
    Score: 0.064
  13. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
    View in: PubMed
    Score: 0.064
  14. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.064
  15. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66.
    View in: PubMed
    Score: 0.062
  16. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
    View in: PubMed
    Score: 0.062
  17. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12.
    View in: PubMed
    Score: 0.060
  18. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22.
    View in: PubMed
    Score: 0.060
  19. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7.
    View in: PubMed
    Score: 0.059
  20. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
    View in: PubMed
    Score: 0.059
  21. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002 Sep; 236(3):376-84; discussion 384-5.
    View in: PubMed
    Score: 0.055
  22. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Target Oncol. 2018 02; 13(1):99-106.
    View in: PubMed
    Score: 0.040
  23. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. Br J Cancer. 2018 02 06; 118(3):331-337.
    View in: PubMed
    Score: 0.040
  24. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.038
  25. MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS One. 2016; 11(3):e0150467.
    View in: PubMed
    Score: 0.035
  26. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013 Sep 15; 119(18):3402-10.
    View in: PubMed
    Score: 0.029
  27. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152.
    View in: PubMed
    Score: 0.028
  28. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.027
  29. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9.
    View in: PubMed
    Score: 0.024
  30. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402.
    View in: PubMed
    Score: 0.024
  31. Influence of age on choice of therapy and surgical outcomes in patients with nonsmall cell lung cancer. Am Surg. 2009 Jul; 75(7):598-603; discussion 603-4.
    View in: PubMed
    Score: 0.022
  32. Superior sulcus tumors with vertebral body involvement: a multimodality approach. J Thorac Cardiovasc Surg. 2009 Jun; 137(6):1379-87.
    View in: PubMed
    Score: 0.022
  33. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009 Oct; 138(4):831-6.
    View in: PubMed
    Score: 0.022
  34. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 2008 Dec; 134(6):1349.
    View in: PubMed
    Score: 0.021
  35. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. J Thorac Oncol. 2007 Nov; 2(11):1022-8.
    View in: PubMed
    Score: 0.020
  36. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007 Aug; 84(2):365-73; discussion 374-5.
    View in: PubMed
    Score: 0.019
  37. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
    View in: PubMed
    Score: 0.018
  38. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006 Feb 01; 106(3):552-8.
    View in: PubMed
    Score: 0.017
  39. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
    View in: PubMed
    Score: 0.017
  40. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005 Dec 01; 104(11):2365-72.
    View in: PubMed
    Score: 0.017
  41. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):700-8.
    View in: PubMed
    Score: 0.017
  42. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005 Oct 01; 104(7):1349-55.
    View in: PubMed
    Score: 0.017
  43. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005 Apr 01; 103(7):1347-55.
    View in: PubMed
    Score: 0.016
  44. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005 Feb 20; 23(6):1136-43.
    View in: PubMed
    Score: 0.016
  45. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res. 2003 Mar; 9(3):1070-6.
    View in: PubMed
    Score: 0.014
  46. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.014
  47. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1216-24.
    View in: PubMed
    Score: 0.014
  48. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.